Trial Profile
A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NT 501 (Primary)
- Indications Choroideraemia; Retinitis pigmentosa; Usher syndromes
- Focus Therapeutic Use
- Sponsors GNT Pharma
- 03 Nov 2014 New trial record